Pitch Sessions: Global Leaders in Brain & Mental Health Innovation

​Mental Health Day, presented by THE REAL Mental Health Foundation & Convergence Partners.

Founders will take us on a journey on how their technology and solutions have changed the game in their respective sectors. With a focus on neurodegenerative diseases and digital therapeutics, these founders provide unique and critical insight to a rapidly growing global unmet prevention , management, and treatment need. Join industry leaders, experts, and investors as we discuss these scalable, evidence-based solutions and the next steps in bringing these solutions to the patient population offering hope and improved quality of life.

Explore all panels: thereal.care/davos

Speakers:
- Guillaume Blivet, Co-founder & CIO, REGEnLIFE
- Dr. Chris Rehese, Founder & CEO, neotiv
- Coming Soon
- Coming Soon

REGEnLIFE:

REGEnLIFE is a French medtech and neurotech company at the forefront of neuroscience innovation, using phototherapy for non-invasive brain-gut stimulation. This novel method shows potential in treating neuroinflammation-related diseases such as Alzheimer's, depression, concussion, and multiple sclerosis. Their cutting-edge device, targeting both brain and gut, aims to enter the neurological disease and mental health market by 2026. Preclinical studies demonstrated safety and efficacy in Alzheimer's, multiple sclerosis, and depression models. First-in-human trials showed promising results in Alzheimer's and sport-related concussion. A pivotal clinical trial for Alzheimer's disease is ongoing, while preparations are underway for market launch in concussion treatment. The therapy is delivered through a helmet and abdominal belt, classified as a Class IIa medical device. This non-invasive, cost-effective solution can be both  administered in hospital or at home. REGEnLIFE holds a robust patent portfolio across various nations, ensuring comprehensive intellectual property control. Financially, the company has secured over €8M in pre-series A funding since its incorporation in 2016 and is now seeking €10M in series A funding to further their advancements. This investment will drive them towards achieving their development goals and potentially revolutionizing brain and mental health.

neotiv
[coming soon]

SwissDTX
[coming soon]

Brainscape
[coming soon]